Last $25.71 USD
Change Today -0.49 / -1.87%
Volume 274.5K
RGEN On Other Exchanges
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

repligen corp (RGEN) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/31/14 - $26.75
52 Week Low
03/27/14 - $12.04
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for REPLIGEN CORP (RGEN)

Related News

No related news articles were found.

repligen corp (RGEN) Related Businessweek News

No Related Businessweek News Found

repligen corp (RGEN) Details

Repligen Corporation, a life sciences company, develops, manufactures, and markets consumable bioprocessing products for use in the production of monoclonal antibodies and other biologic drugs. The company manufactures various forms of Protein A, a critical reagent used in biomanufacturing to separate and purify monoclonal antibodies. It also supplies various growth factor products, which are used to increase cell growth and productivity during upstream fermentation. In addition, the company manufactures and sells chromatography products, including OPUS pre-packed columns for biologics purification, as well as proprietary Protein A media and quality test kits. Further, it has a portfolio of therapeutic product candidates, which include RG3039, a small molecule drug candidate in clinical development for spinal muscular atrophy; histone deacetylase inhibitor for the treatment of Friedreich’s ataxia disease; and RG1068, a synthetic human hormone developed as a novel imaging agent for the detection of pancreatic duct abnormalities in combination with magnetic resonance imaging in patients with pancreatitis and other related diseases. Additionally, Repligen Corporation offers alternating tangential flow system, a filtration device used to improve product yields during the fermentation step of the biologic drug manufacturing process. The company sells its bioprocessing products are to various life sciences companies, biopharmaceutical manufacturing companies, and contract manufacturing organizations worldwide. Repligen Corporation was founded in 1981 and is headquartered in Waltham, Massachusetts.

116 Employees
Last Reported Date: 03/14/14
Founded in 1981

repligen corp (RGEN) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $475.0K
Senior Vice President of Research & Developme...
Total Annual Compensation: $293.0K
Vice President of Business Development
Total Annual Compensation: $262.5K
Senior Advisor
Total Annual Compensation: $272.5K
Compensation as of Fiscal Year 2013.

repligen corp (RGEN) Key Developments

Repligen Completes Expansion of U.S. Manufacturing Facility

Repligen Corporation announced that it has completed an 11,000 square foot expansion of its U.S. manufacturing facility. The expansion includes a dedicated space for the production and assembly of Repligen's Alternating Tangential Flow System (‘the ATF System’), the most recent addition to the Company's upstream bio processing product portfolio. The ATF System is a product line used to significantly increase cell density and product yield during the fermentation step of the biologic drug manufacturing process. The expansion includes areas for ATF System assembly, quality control and inventory, as well as clean room suites for the production of single-use ATF Systems in an ISO 7 environment that meets the high standards of Repligen's biopharmaceutical customers. The facility upgrade also expands on areas dedicated to cell culture research and development as well as manufacturing and support of the company's ELISA test kits and its OPUS line of pre-packed chromatography columns. An additional 7,500 square feet is reserved for future expansion of the Waltham facility, allowing the company to remain flexible and responsive to the needs of its biopharmaceutical customers and life sciences partners.

Repligen Corporation Presents at Leerink's Global Healthcare Conference, Feb-12-2015 02:40 PM

Repligen Corporation Presents at Leerink's Global Healthcare Conference, Feb-12-2015 02:40 PM. Venue: Waldorf Astoria New York, New York, New York, United States. Speakers: Walter C. Herlihy, Chief Executive Officer, President, Director and Chairman of Science & Technology Committee.

Repligen Corporation Announces Termination of License Agreement with Pfizer Inc., Effective as of April 26, 2015

On January 26, 2015, Pfizer Inc. issued to Repligen Corporation a notice of termination for convenience under the License Agreement, dated December 28, 2012, by and between the company and Pfizer Inc. for the development of compounds to treat spinal muscular atrophy (SMA). The termination of the License Agreement will become effective as of April 26, 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGEN:US $25.71 USD -0.49

RGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RGEN.
View Industry Companies

Industry Analysis


Industry Average

Valuation RGEN Industry Range
Price/Earnings 71.4x
Price/Sales 13.4x
Price/Book 7.3x
Price/Cash Flow 70.7x
TEV/Sales 12.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REPLIGEN CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at